2rounds
0led
Fintech 2
Series C+ 2
US startup investors — January 2026 · Jan 1, 2026 – Jan 31, 2026
Recent funding activity in US startups, organised by investor and their role in each round.
Browse by month
2rounds
—led
Cybersecurity 1Fintech 1
Series A 1, Undisclosed 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
Project Eleven $20M Series AWitnessAI $58M Strategic2rounds
—led
AI 1Foodtech 1
Seed 1, Undisclosed 1
Details
New companies 2 · Follow-on 0
Stages: Seed 1, Undisclosed 1
VoiceRun $5.5M SeedPresto Phoenix $10M Undisclosed2rounds
—led
Biotech 1Healthtech 1
Series A 2
Details
New companies 2 · Follow-on 0
Stages: Series A 2
Caldera Therapeutics $37.5M Series A1Spiro Medical $67M Series A2rounds
0led
Fintech 2
Seed 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Seed 1, Series C+ 1
Alpaca $150M Series DPluto Financial Technologies $8.6M Seed2rounds
—led
Climate tech 1Cybersecurity 1
Undisclosed 2
Details
New companies 2 · Follow-on 0
Stages: Undisclosed 2
Amperon Undisclosed UndisclosedWitnessAI $58M Strategic2rounds
—led
Enterprise software 1Healthtech 1
Undisclosed 2
Details
New companies 2 · Follow-on 0
Stages: Undisclosed 2
StarLIMS Undisclosed UndisclosedAvalon Healthcare Solutions Undisclosed Undisclosed2rounds
—led
AI 2
Series A 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
Deepgram $130M Series CSpangle AI $15M Series A2rounds
—led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Mirador Therapeutics $250M Series BParabilis Medicines $305M Series F2rounds
—led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Mirador Therapeutics $250M Series BParabilis Medicines $305M Series F2rounds
—led
Biotech 1Healthtech 1
Series A 1, Undisclosed 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
VieCure $43M UndisclosedVizgen $48M Series A2rounds
—led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Kinaset Therapeutics $103M Series BParabilis Medicines $305M Series F2rounds
—led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Kinaset Therapeutics $103M Series BParabilis Medicines $305M Series F2rounds
—led
Biotech 2
Series B 2
Details
New companies 2 · Follow-on 0
Stages: Series B 2
Kinaset Therapeutics $103M Series BEpiBiologics $107M Series B2rounds
—led
Defense tech 1Industrial tech 1
Series A 1, Undisclosed 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
Hadrian Undisclosed UndisclosedValinor Enterprises $54M Series A2rounds
—led
Biotech 2
Series A 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
AirNexis Therapeutics $200M Series AParabilis Medicines $305M Series F2rounds
—led
Biotech 1Healthtech 1
Series A 2
Details
New companies 2 · Follow-on 0
Stages: Series A 2
Ventaris Surgical $30M Series AAirNexis Therapeutics $200M Series A2rounds
—led
Biotech 1Healthtech 1
Series A 2
Details
New companies 2 · Follow-on 0
Stages: Series A 2
AirNexis Therapeutics $200M Series APoplar Therapeutics $50M Series A2rounds
—led
Developer tools 1Industrial tech 1
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Luxury Presence $37M Series CCambium $100M Series B2rounds
—led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
EpiBiologics $107M Series BParabilis Medicines $305M Series F1rounds
—led
Healthtech 1
Pre-seed 1
Details
1rounds
—led
Industrial tech 1
Series C+ 1
Details
1rounds
—led
Industrial tech 1
Series C+ 1
Details
1rounds
—led
Biotech 1
Undisclosed 1
Details
1rounds
—led
Healthtech 1
Pre-seed 1
Details
1rounds
—led
Healthtech 1
Pre-seed 1
Details
1rounds
—led
Healthtech 1
Pre-seed 1
Details
1rounds
—led
Healthtech 1
Pre-seed 1
Details
1rounds
—led
Industrial tech 1
Series C+ 1
Details
1rounds
—led
AI 1
Seed 1
Details
“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.